Late-breaking oral presentation to highlight further evidence supporting potential for deupirfenidone to serve as a new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF) ...

Pulmonary fibrosis is a growing global health concern with varying epidemiological trends. In Western populations, IPF prevalence ranges from 2 to 29 cases per 100,000 individuals, with incidence ...

Environmental and Occupational Exposure: Chronic inhalation of inorganic and organic particulates, such as silica, asbestos, ...

The outcomes of patients with idiopathic pulmonary fibrosis (IPF) remain unknown. Alongside the global adoption of antifibrotic therapies, there is currently relentless research for biomarkers and ...

Panelists discuss how novel targeted therapies for immunoglobulin A (IgA) nephropathy are transforming treatment paradigms by ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Sagimet Biosciences (SGMT) announced that three poster presentations featuring additional analyses from the Phase 2b FASCINATE-2 study of ...

STOCKHOLM, SE / ACCESS Newswire / April 23, 2025 / Vicore Pharma Holding (STO:VICO) Stockholm, April 23, 2025 - Vicore Pharma Holding AB (STO: VICO), unlocking the potential of a novel class of drugs, ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs ...

Liver fibrosis is a key process in the progression of chronic liver diseases. However, there are currently no drugs specifically designed to treat ...

There is no cure, but approved antifibrotic medications can slow progression. Ongoing research aims to deepen understanding of the disease and enable more precisely targeted therapies.